Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on NeuroPace, Inc. (NASDAQ:NPCE) on July 29, 2026.
reiterateNASDAQ:NPCE
HC Wainwright & Co. Reiterates Buy Rating on NeuroPace, Inc. (NPCE)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on NeuroPace, Inc. (NASDAQ:NPCE) on July 29, 2026.
Market Context
NeuroPace, Inc. operates in the Healthcare sector. The stock currently trades at $15.31 with a market capitalization of $548.9M. The stock has gained 61.0% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for NeuroPace, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for NeuroPace, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 29, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 23, 2026 | Mizuho | Outperform | N/A |
| May 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jan 27, 2026 | HC Wainwright & Co. | Buy | N/A |
| Dec 16, 2025 | UBS | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NPCE Stock Page
Frequently Asked Questions
What does a Buy rating mean for NPCE?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on NeuroPace, Inc. (NASDAQ:NPCE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NPCE forecast page.